How do MAO-B inhibitors improve Parkinson's symptoms?

MAO-B inhibitors improve symptoms of Parkinson's disease primarily by inhibiting the breakdown of dopamine. In the context of Parkinson's disease, there is a deficiency of dopamine due to the degeneration of dopaminergic neurons in the brain. MAO-B (monoamine oxidase B) is an enzyme that specifically breaks down dopamine in the brain. By blocking this enzyme, MAO-B inhibitors prevent the degradation of dopamine, thereby increasing its availability and enhancing dopaminergic signaling.

This increase in dopamine levels can lead to an improvement in motor control and a reduction in the characteristic symptoms of Parkinson’s disease, such as tremors and rigidity. The effect of these medications can manifest as a reduction in the severity of symptoms, allowing for greater functional mobility and quality of life for patients.

The other options primarily involve neurotransmitters or mechanisms that do not directly relate to the primary action of MAO-B inhibitors in the context of Parkinson's treatment.